Although Lck interaction with Tau has also been reported [145], Fyn has emerged as a prime target for preclinical therapeutic intervention with SFK inhibitor saracatinib in Alzheimer disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.